Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."

Google Search: Crystal Ball for Election Results?
58:08 - Khosla Ventures partner Keith Rabois, Braintree head of commerce Harper Reed and Bloomberg’s Tim Higgins discuss how campaigns can use Google search data with Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Apple Said to Produce New Show Starring Dr. Dre
  • Can PayPal Commerce Stand Up to Competition?
  • How Medium Recruits High Profile Writers